Fundraising FoxiosBio
2 known investors
Find your way into iosBio
Sign up to see every warm intro you have to iosBio
- Paths you didn't know you had: your email and LinkedIn already hold routes to the iosBio team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
iosBio develops oral, thermostable vaccine candidates using its ESD platform, with a lead program (OraPro-EBV) targeting Epstein-Barr Virus. The company operates in the biotechnology and vaccine development sector.
Founders & leadership
WC
Wayne ChannonExecutive ChairmanWayne Channon holds a degree in mathematical physics from Imperial College and worked as a systems engineer at IBM. He founded Persona, a networking and communications distributor that grew to €500m in revenue and listed on the London Stock Exchange, and has since founded multiple technology and life sciences companies including Cells4Life and CyteTech. He chairs iosBio, which develops oral thermostable vaccine candidates.
EB
Elliot BlandCOOElliot Bland is COO at iosBio and a life science executive with a PhD in immunology and expertise in vaccine development, including patent work on EBV antigens. He has previously held senior operations and business development roles at early-stage biotechnology companies, with experience in fundraising, licensing, and regulatory navigation.
Investors · 2
Companies House · registry record
View on Companies House ↗- Registered name
- IOSBIO LTD
- Company number
- 04497290
- Status
- Active
- Company type
- Private limited company
- Incorporated
- 29 Jul 2002
- Registered office
- Hayworthe House, Market Place, Haywards Heath, RH16 1DB
- Nature of business (SIC)
- 86900 — Other human health activities
- Previous names
- STABILITECH BIOPHARMA LTD (2016–2020)STABILITECH LTD (2002–2016)
- Accounts
- last made up to 31 Jul 2025 · next due 30 Apr 2027
- Confirmation statement
- last made up to 5 Nov 2025 · next due 19 Nov 2026
Current officers · 6
- Colin Neil Maltby — secretary, appointed 26 Aug 2020
- Elliot Bland — director, appointed 16 Jan 2018
- Wayne Matthew Channon — director, appointed 26 Mar 2007
- Peter John Cozens — director, appointed 5 Feb 2009
- Craig Antony Joseph Laferriere — director, appointed 16 Jul 2024
- Myra Nicole Waiman — director, appointed 6 Jan 2015
Source: Companies House public register · retrieved 16 Aug 2026. Contains public sector information licensed under the Open Government Licence v3.0.
Frequently asked questions
- What does iosBio do?
- iosBio develops oral, thermostable vaccine candidates using its ESD platform, with a lead program (OraPro-EBV) targeting Epstein-Barr Virus. The company operates in the biotechnology and vaccine development sector.
- Who are iosBio's investors?
- iosBio's investors include Innvotec Ltd., Shackleton Ventures Ltd..